Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016923
Chunk: 163

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 163
---
ensed Consolidated Financial Statements (unaudited)</div>

| Condensed Consolidated                                                                
 Balance Sheets at March 31, 2025 (unaudited) and December 31, 2024                    
 Unaudited Condensed Consolidated                                                      
 Statements of Operations for the Three Months ended March 31, 2025 and 2024           | F-2 
 F-3 |
|:--------------------------------------------------------------------------------------|:----|
| Unaudited Condensed Consolidated                                                      
 Statements of Stockholders’ Equity for the Three Months ended March 31, 2025 and 2024 | F-4 |
| Unaudited Condensed Consolidated                                                      
 Statements of Cash Flows for the Three Months ended March 31, 2025 and 2024           | F-5 |
| Notes to Unaudited Condensed                                                          
 Consolidated Financial Statements                                                     | F-6 |

<div align='center'>Index to the Consolidated Financial Statements</div>

| Report of Independent Registered Public Accounting Firm (PCAOB ID NO. 100)                                                                
 Consolidated Balance Sheets as of December 31, 2024 and 2023                                                                              
 Consolidated Statements of Operations for the years ended December 31, 2024 and 2023                                                      | F-15 
 F-16 
 F-17 |
|:------------------------------------------------------------------------------------------------------------------------------------------|:-----|
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity for the years ended December 31, 2024 and 2023 | F-18 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023                                                      | F-19 |
| Notes to Consolidated Financial Statements                                                                                                | F-20 |

| F-1 |

<div align='center'>bioAffinity Technologies, Inc.

Consolidated Balance Sheets</div>

|                                                                                         |     | March    
 31, 2025 |             |   |     | December 
 31, 2024 |             |   |
|:----------------------------------------------------------------------------------------|:----|:---------|------------:|:--|:----|:---------|------------:|:--|
|                                                                                         |     |          |  -unaudited |   |     |          |             |   |
| ASSETS                                                                                  |     |          |             |   |     |          |             |   |
| Current assets:                                                                         |     |          |             |   |     |          |             |